CRISPR Therapeutics AG (NASDAQ:CRSP) COO Julianne Bruno Sells 1,198 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) COO Julianne Bruno sold 1,198 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now owns 8,263 shares of the company’s stock, valued at $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

CRISPR Therapeutics Stock Up 2.6 %

NASDAQ:CRSP opened at $43.49 on Thursday. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $76.86. The stock’s fifty day moving average is $43.02 and its two-hundred day moving average is $45.65. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of -9.95 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Institutional Trading of CRISPR Therapeutics

Several hedge funds have recently modified their holdings of the stock. Capital Market Strategies LLC purchased a new stake in CRISPR Therapeutics during the 4th quarter worth about $461,000. KBC Group NV grew its position in shares of CRISPR Therapeutics by 2,047.4% during the fourth quarter. KBC Group NV now owns 60,514 shares of the company’s stock worth $2,382,000 after buying an additional 57,696 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after buying an additional 35,196 shares during the period. State Street Corp raised its holdings in CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after acquiring an additional 599,304 shares in the last quarter. Finally, ARK Investment Management LLC lifted its stake in CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after acquiring an additional 1,474,439 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Citigroup lowered their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research note on Tuesday, February 18th. Barclays increased their price objective on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. JMP Securities restated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. The Goldman Sachs Group dropped their price target on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Finally, Morgan Stanley lifted their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.